Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-001 with Paclitaxel in Recurrent Ovarian and Endometrial Cancer
NCT06620029Phase 2Not yet recruiting
- Sponsor
- BioMimetix
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of manganese butoxyethyl pyridyl porphyrin in ovarian cancer and endometrial cancer (EC), sponsored by BioMimetix. Primary endpoint: Recommended Phase 2 Dose at 8 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
manganese butoxyethyl pyridyl porphyrin
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06620029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620029.